Research programme: herbal therapeutics - Kadmon Corporation
Alternative Names: PHY626; PHY777; PHY808Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator PhytoCeutica
- Developer Kadmon Corporation
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation; Myelosuppression
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myelosuppression(Chemotherapy-induced) in USA